Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Tetra Bio-Pharma Announces Listing to OTCPink Market PR Newswire MONTREAL, Feb. 10, 2023 MONTREAL, Feb. 10, 2023 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the...
REDUVO™ Marketing Approval on the Right Path PR Newswire MONTREAL, Dec. 22, 2022 Second Clarifax received from Health Canada.MONTREAL, Dec. 22, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc...
Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir PR Newswire MONTREAL, Dec. 6, 2022 The combination of ARDS-003 and Favipiravir presents...
Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003 PR Newswire MONTREAL, Nov. 29, 2022 Tetra strengthens its intellectual property position with PCT and...
Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission PR Newswire MONTREAL, Nov. 18, 2022 MONTREAL, Nov. 18, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or...
Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean PR Newswire OTTAWA, ON, Oct. 27, 2022 OTTAWA, ON, Oct. 27, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc...
Tetra and Prepaire Jointly Apply to BARDA for Funding PR Newswire OTTAWA, ON, Oct. 11, 2022 Companies jointly submitted a $750,000 USD application to BARDA to use Prepaire™ Shield discovery...
Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean PR Newswire OTTAWA, ON, Sept. 8, 2022 OTTAWA, ON, Sept. 8, 2022 /PRNewswire/ - Tetra Bio-Pharma...
Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients PR Newswire OTTAWA, ON, Sept. 6, 2022 Tetra and Cellvera to jointly develop an orally...
Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean PR Newswire OTTAWA, ON, Aug. 11, 2022 OTTAWA, ON, Aug. 11, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.025 | 0.025 | 0.025 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.025 | 0.025 | 0.025 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.025 | 0.025 | 0.025 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.025 | 0.025 | 0.025 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.025 | 0.025 | 0.025 | 0 | 0 | CS |
| 156 | -0.1 | -80 | 0.125 | 0.14 | 0.015 | 255160 | 0.04677948 | CS |
| 260 | -0.205 | -89.1304347826 | 0.23 | 0.53 | 0.015 | 612751 | 0.21302326 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
